Collegium Pharmaceutical, Inc (COLL): who owns it and who trades it
As of Nov 16, 2026, COLL insiders reported 11 open-market sales worth $4.4M and no purchases in the last 12 months, with 82% of the sale value made under pre-set 10b5-1 plans. The largest seller was Scott Dreyer (Vice president), with $2.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Collegium Pharmaceutical
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns COLL
277 funds and institutions reported COLL shares worth $1.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.44M | 16.78% | $197M | +6% |
| Jupiter Topco LLC | 2.15M | 6.62% | $77.7M | – |
| Invesco Ltd. | 1.88M | 5.80% | $68.1M | +18% |
| Fuller & Thaler Asset Management, Inc. | 1.63M | 5.03% | $59.1M | +9% |
| Principal Financial Group Inc | 1.63M | 5.03% | $59.1M | +26% |
| California State Teachers Retirement System | 1.55M | 4.78% | $42.8M | +5166% |
| State Street Corp | 1.53M | 4.71% | $55.3M | +7% |
| Massachusetts Financial Services Co | 1.41M | 4.33% | $50.9M | +3% |
| Vanguard Capital Management LLC | 1.38M | 4.26% | $50M | +4% |
| Renaissance Technologies LLC | 1.37M | 4.21% | $49.5M | -7% |
| Eventide Asset Management, LLC | 1.36M | 4.20% | $49.3M | -4% |
| Rubric Capital Management LP | 1.28M | 3.95% | $46.3M | No change |
| Geode Capital Management, LLC | 890,886 | 2.75% | $32.3M | +9% |
| Dimensional Fund Advisors LP | 837,877 | 2.58% | $30.3M | +1% |
| Victory Capital Management Inc | 760,252 | 2.34% | $27.5M | +22% |
| Goldentree Asset Management LP | 744,889 | 2.30% | $26.9M | – |
| Vanguard Portfolio Management LLC | 740,081 | 2.28% | $26.8M | +9% |
| Millennium Management LLC | 736,925 | 2.27% | $26.7M | +104% |
| Arrowstreet Capital, Limited Partnership | 621,920 | 1.92% | $22.5M | -12% |
| Assenagon Asset Management S.A. | 617,834 | 1.90% | $22.4M | +98% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, COLL insiders reported $0 of open-market purchases and $4.4M of sales. 82% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | John Gordon Freund | Director | Sale | 20 | $34.05 | $681 | Form 4 |
| May 15, 2026 | John Gordon Freund | Director | Sale | 4,127 | $34.54 | $143K | Form 4 |
| May 13, 2026 | Nancy Lurker | Director | Sale | 4,500 | $35.97 | $162K | Form 4 |
| May 11, 2026 | Garen G Bohlin | Director | Sale | 8,700 | $37.18 | $323K | Form 4 |
| Mar 18, 2026 | David Dieter | Vice president | Sale plan | 13,976 | $34.92 | $488K | Form 4 |
| Mar 9, 2026 | David Dieter | Vice president | Sale plan | 6,224 | $36.65 | $228K | Form 4 |
| Mar 3, 2026 | Scott Dreyer | Vice president | Sale plan | 3,559 | $40.99 | $146K | Form 4 |
| Mar 3, 2026 | Scott Dreyer | Vice president | Sale plan | 46,417 | $40.36 | $1.9M | Form 4 |
| Dec 8, 2025 | Scott Dreyer | Vice president | Sale plan | 11,125 | $47.89 | $533K | Form 4 |
| Dec 8, 2025 | Scott Dreyer | Vice president | Sale plan | 6,475 | $48.66 | $315K | Form 4 |
| Dec 5, 2025 | Rita J. Balice-Gordon | Director | Sale | 3,650 | $47.03 | $172K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Scott Dreyer | EVP & Chief Commercial Officer | – | $2.9M | Mar 3, 2026 |
| David Dieter | EVP & General Counsel | – | $716K | Mar 18, 2026 |
| Garen G Bohlin | Director | – | $323K | May 11, 2026 |
| Rita J. Balice-Gordon | Director | – | $172K | Dec 5, 2025 |
| Nancy Lurker | Director | – | $162K | May 13, 2026 |
| John Gordon Freund | Director | – | $143K | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
COLL short interest
High short interest. 16.0% of COLL shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.19M COLL shares were sold short, 16.0% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 552,891 shares, buying them all back would take about 9.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.19M | 15.96% | -3% | 552,891 | 9.4 |
| Oct 15, 2026 | 5.38M | 16.51% | -3% | 749,870 | 7.2 |
| Sep 30, 2026 | 5.52M | 16.95% | -3% | 910,922 | 6.1 |
| Sep 15, 2026 | 5.68M | 17.43% | -6% | 941,430 | 6.0 |
| Aug 31, 2026 | 6.06M | 18.63% | -7% | 750,635 | 8.1 |
| Aug 14, 2026 | 6.52M | 20.04% | +28% | 979,471 | 6.7 |
| Jul 31, 2026 | 5.08M | 15.61% | -3% | 292,836 | 17.4 |
| Jul 15, 2026 | 5.23M | 16.14% | -4% | 467,575 | 11.2 |
| Jun 30, 2026 | 5.47M | 16.85% | +3% | 504,462 | 10.8 |
| Jun 15, 2026 | 5.33M | 16.43% | -6% | 407,626 | 13.1 |
| May 29, 2026 | 5.66M | 17.46% | -5% | 318,273 | 17.8 |
| May 15, 2026 | 5.97M | 18.39% | +0% | 533,619 | 11.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Collegium Pharmaceutical company events
Collegium Pharmaceutical filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 19, 2026AgreementEnded an important agreement. Filing
- Aug 13, 2026AnnouncementCollegium Pharmaceutical, Inc. announced the execution of an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 15, 2026VoteReported shareholder vote results. Filing
- May 12, 2026LeadershipThe Company’s board of directors adopted the Company’s 2026 Inducement Plan, pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with respect to an… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 7, 2026LeadershipThe board of directors of Collegium Pharmaceutical, Inc. approved the nomination of Michael Donovan to stand for election at the Company’s 2026 Annual Meeting of Shareholders. Filing
- Mar 19, 2026AgreementCollegium Pharmaceutical, Inc., entered into an Equity Purchase Agreement with Corium Therapeutics Holdings, LLC, a Delaware limited liability company, and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and, together with Commave Seller, the “ Seller Parties ” and each, a “… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementShared information with investors. Filing
- Dec 30, 2025AgreementEntry into a Material Agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Collegium Pharmaceutical financials
Famous investors that hold COLL
4 of the 50 well-known investors we track reported holding COLL in their latest 13F filing. The largest position is Israel Englander's, worth $52.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.40M | $52.4M | 0.0% | +226% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.41M | $30.7M | 0.0% | +3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 602,530 | $13.1M | 0.0% | +778% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 209,797 | $4.6M | 0.0% | +84% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named COLL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 0.2% |
| Nov 16, 2026 | FULLER & THALER ASSET MANAGEMENT, INC. | 13G/A | 1.8% |
| Nov 16, 2026 | FULLER & THALER ASSET MANAGEMENT, INC. | 13G/A | 1.8% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 0.2% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.4% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 3.9% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 3.9% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 5.0% |
| Oct 29, 2026 | PRINCIPAL GLOBAL INVESTORS | 13G/A | 4.7% |
| Oct 29, 2026 | PRINCIPAL GLOBAL INVESTORS | 13G/A | 4.7% |
| Oct 8, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 5.8% |
| Oct 8, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 5.8% |
Questions about Collegium Pharmaceutical, Inc (COLL) stock
Who owns the most COLL stock?
The largest reported owner of Collegium Pharmaceutical, Inc (COLL) is BlackRock, Inc., with 16.8% of the company. In total, 277 funds and institutions reported holding COLL at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are COLL insiders buying or selling?
In the last 12 months, COLL insiders reported no open-market purchases and 11 sales worth $4.4M. The latest trade was on May 18, 2026. See every trade.
What is the short interest in COLL?
As of Oct 30, 2026, 5.19M COLL shares were sold short, 16.0% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 552,891 shares, buying them all back would take about 9.4 trading days (days to cover). See the history.
Which famous investors hold COLL?
4 of the 50 well-known investors we track reported COLL in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $52.4M. See all holders.
Executive pay
Collegium Pharmaceutical's chief executive was paid a total of $1.7M for the year ended Dec 31, 2025. In the last 12 months, Collegium Pharmaceutical's executives and directors bought no stock on the open market and sold $4.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.